HemaCare Corporation Share Price

HEMA

US4234981045

Healthcare Facilities & Services

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.08%	+0.24%

02/06/20	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
21/01/20	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI

Valuation: HemaCare Corporation

Market Cap	346M 304M 288M 260M 491M 33.15B 497M 3.45B 1.33B 16.95B 1.3B 1.27B 54.33B	P/E 2017	8.18x	P/E 2018	27.6x
Enterprise Value	336M 296M 280M 253M 477M 32.2B 483M 3.35B 1.29B 16.46B 1.26B 1.23B 52.77B	EV / Sales 2017	1.29x	EV / Sales 2018	4.03x
Free-Float	94.17%	Yield 2017 *	-	Yield 2018	-

* Estimated data More valuation ratios

Latest news: HemaCare Corporation

02/06/20	HemaCare Corporation Adds GMPrime Cryopreserved Leukopak to its GMP Product Portfolio	CI
21/01/20	MicroMedicine and HemaCare Announces Cooperative Efforts to Improve Cell Therapy Starting Materials	CI
02/01/20	Charles River Laboratories International, Inc. completed the acquisition of HemaCare Corporation.	CI
15/12/19	Charles River Laboratories International, Inc. entered into a definitive agreement to acquire HemaCare Corporation for approximately $380 million.	CI
19/11/19	HemaCare Expands Its Product Portfolio with GMPrime™ Bone Marrow Aspirate	CI
27/08/19	HemaCare Corporation and Vital River Partner to Provide Human-Derived Biological Material to China	CI
20/08/19	Hemacare Corporation Reports Earnings Results for the Half Year Ended June 30, 2019	CI
26/03/19	HemaCare Corporation Reports Earnings Results for the Year Ended December 31, 2018	CI
19/12/18	HemaCare Corporation announced that it has received $4.999999 million in funding from OBF Investments LLP	CI
06/12/18	HemaCare Corporation Moves its Global Headquarters to Northridge, California	CI
14/11/18	HemaCare Corporation Provides Starting Material for Three FDA Approved Cellular Therapies	CI
21/08/18	HemaCare Corporation Reports Unaudited Earnings Results for the Six Months Ended June 30, 2018	CI
17/07/18	HemaCare Corporation Announces Executive Appointments	CI

More news

Press Releases: HemaCare Corporation

16/12/19

HEMACARE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of HEMA and Encourages Investors to Contact the Firm

More press releases

Managers and Directors: HemaCare Corporation

Manager	Title	Age	Since
Colin S. Dunn CEO	Chief Executive Officer	-	-
Samira Amini DFI	Director of Finance/CFO	-	-
Maria Pia Muniz COO	Chief Operating Officer	-	31/12/2002

Director	Title	Age	Since
Colin S. Dunn BRD	Director/Board Member	-	-
Samira Amini BRD	Director/Board Member	-	-
Emily Nekimken BRD	Director/Board Member	-	-

More insiders

Other Healthcare Facilities & Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMACARE CORPORATION	-.--%	+0.08%	-	-	346M
CVS HEALTH CORPORATION	-1.62%	-0.20%	+13.66%	+22.73%	110B
HCA HEALTHCARE, INC.	-1.13%	-2.23%	+0.13%	+73.49%	92.39B
NATERA, INC.	-0.29%	+5.76%	+156.76%	+834.03%	59.58B
FRESENIUS SE & CO. KGAA	+0.50%	-4.41%	-6.75%	+50.03%	28.62B
QUEST DIAGNOSTICS INCORPORATED	+0.47%	+0.03%	+22.30%	+91.26%	25.72B
LABCORP HOLDINGS INC.	-0.23%	+1.36%	+7.33%	+53.25%	24.99B
TENET HEALTHCARE CORPORATION	-0.79%	-0.34%	+25.87%	+287.86%	20.58B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.57%	-0.04%	-16.08%	-6.45%	21.11B
IHH HEALTHCARE	-1.66%	-4.47%	-3.02%	+33.22%	16.95B
Average	-0.35%	-0.25%	+22.24%	+159.94%	39.99B
Weighted average by Cap.	-0.29%	-0.07%	+28.92%	+176.28%

See all sector performances

Charles River Laboratories Cell Solutions, Inc. is a cell sourcing provider for developers of cell therapies and basic research. The Company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. It offers a comprehensive and integrated portfolio of drug development products and services available from a single global provider, spanning the continuum from early research to the support of marketed products. Its products and services include Research Models & Services, Discovery Services Safety Assessment, Laboratory Sciences, Cell and Gene Therapy CDMO Solutions, Biologics Testing Solutions, Avian Vaccine Services, QC Microbial Solutions, Scientific & Regulatory Advisory Services, and Scientific Staffing, Training & Operations Support.

Employees

Sector

Healthcare Facilities & Services

More about the company

Stock Market
Stocks
HEMA Stock

As early as today, start finding the best investment opportunities!

	2017	2018
Net sales	20.21M 17.8M 16.86M 15.22M 28.69M 1.94B 29.06M 202M 77.64M 991M 75.9M 74.24M 3.18B	28.51M 25.1M 23.78M 21.47M 40.47M 2.73B 40.99M 285M 110M 1.4B 107M 105M 4.48B
Net income	4.43M 3.9M 3.7M 3.34M 6.29M 425M 6.37M 44.24M 17.03M 217M 16.64M 16.28M 696M	4.52M 3.98M 3.77M 3.4M 6.41M 433M 6.49M 45.08M 17.35M 221M 16.96M 16.59M 710M
Net Debt	-9.06M -7.98M -7.56M -6.82M -12.86M -869M -13.03M -90.43M -34.8M -444M -34.02M -33.27M -1.42B	-9.9M -8.72M -8.26M -7.45M -14.05M -949M -14.23M -98.8M -38.02M -485M -37.16M -36.35M -1.56B

HemaCare Corporation Share Price

Stocks

HEMA

US4234981045

Healthcare Facilities & Services

Valuation: HemaCare Corporation

Latest news: HemaCare Corporation

Press Releases: HemaCare Corporation

Managers and Directors: HemaCare Corporation

Other Healthcare Facilities & Services

Financials

Company Profile